
Single-agent immunotherapy was a good start. Anti-PD-1 alone delivers durable responses in melanoma, lung cancer, and a handful of other tumor types. But for most cancers, monotherapy response rates hover in the 15-25% range, which means the majority of patients get the side effects without the...








